{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:50:01Z","timestamp":1760205001635,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T00:00:00Z","timestamp":1549497600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12879-019-3768-y","type":"journal-article","created":{"date-parts":[[2019,2,7]],"date-time":"2019-02-07T14:04:12Z","timestamp":1549548252000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A case report of severe recurrent varicella in an ankylosing spondylitis patient treated with adalimumab \u2013 a new side effect after 15\u2009years of usage"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0129-1519","authenticated-orcid":false,"given":"Tomislava","family":"Skuhala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Atelj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jelena","family":"Prepolec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Al-Mufleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrija","family":"Stanimirovi\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalibor","family":"Vukeli\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,7]]},"reference":[{"key":"3768_CR1","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1001\/archneurol.2011.3741","volume":"69","author":"W Baek","year":"2012","unstructured":"Baek W, Lee SG, Kim YS, Kim JH, Jun JB, Kim HY. Fatal varicella-zoster virus vasculopathy associated with adalimumab therapy. Arch Neurol. 2012;69:1193\u20136.","journal-title":"Arch Neurol"},{"key":"3768_CR2","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.idc.2010.01.006","volume":"24","author":"S Koo","year":"2010","unstructured":"Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin N Am. 2010;24:285.","journal-title":"Infect Dis Clin N Am"},{"key":"3768_CR3","first-page":"79e99","volume":"5","author":"T Ali","year":"2013","unstructured":"Ali T, Kaitha S, Mahmood S, Ftesi A, Stone J, Bronze MS. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf. 2013;5:79e99.","journal-title":"Drug Healthc Patient Saf"},{"key":"3768_CR4","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","volume":"24","author":"JW Baddley","year":"2018","unstructured":"Baddley JW, Cantini F, Goletti D, G\u00f3mez-Reino JJ, Mylonakis E, San-Juan R, et al. ESCMID study Group for Infections in compromised hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [I]: anti-tumor necrosis factor-\u03b1 agents). Clin Microbiol Infect. 2018;24:S10\u201320.","journal-title":"Clin Microbiol Infect"},{"key":"3768_CR5","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1592\/phco.2005.25.9.1181","volume":"25","author":"DJ Rychly","year":"2005","unstructured":"Rychly DJ, DiPiro JT. Infections associated with tumor necrosis factor-alpha antagonists. Pharmacotherapy. 2005;25:1181\u201392.","journal-title":"Pharmacotherapy"},{"key":"3768_CR6","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/1756-185X.12659","volume":"19","author":"C Downey","year":"2016","unstructured":"Downey C. Serious infection during etanercept, infliximab and adalimumab therapy for rheumatoid arthritis: a literature review. Int J Rheum Dis. 2016;19:536\u201350.","journal-title":"Int J Rheum Dis"},{"key":"3768_CR7","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1136\/ard.2009.125658","volume":"69","author":"I Garc\u00eda-Doval","year":"2010","unstructured":"Garc\u00eda-Doval I, P\u00e9rez-Zafrilla B, Descalzo MA, Rosell\u00f3 R, Hern\u00e1ndez MV, G\u00f3mez-Reino JJ, et al. Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis. 2010;69:1751\u20135.","journal-title":"Ann Rheum Dis"},{"key":"3768_CR8","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2009.146","volume":"301","author":"A Strangfeld","year":"2009","unstructured":"Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA. 2009;301:737\u201344.","journal-title":"JAMA"},{"key":"3768_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.jbspin.2016.04.001","volume":"84","author":"CT Tran","year":"2017","unstructured":"Tran CT, Ducancelle A, Masson C, Lunel-Fabiani F. Herpes zoster: risk and prevention during immunomodulating therapy. Joint Bone Spine. 2017;84:21\u20137.","journal-title":"Joint Bone Spine"},{"key":"3768_CR10","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1111\/j.1572-0241.2004.41389_7.x","volume":"99","author":"VS Leung","year":"2004","unstructured":"Leung VS, Nguyen MT, Bush TM. Disseminated primary varicella after initiation of infliximab for Crohn\u2019s disease. Am J Gastroenterol. 2004;99:2503\u20134.","journal-title":"Am J Gastroenterol"},{"key":"3768_CR11","first-page":"2517","volume":"31","author":"H Vonkeman","year":"2004","unstructured":"Vonkeman H, ten Napel C, Rasker H, van de Laar M. Disseminated primary varicella infection during infliximab treatment. J Rheumatol. 2004;31:2517\u20138.","journal-title":"J Rheumatol"},{"key":"3768_CR12","first-page":"54","volume":"9","author":"SM Elwir","year":"2013","unstructured":"Elwir SM, Shaffer CC, Arvan SW, Kuperman EF. Disseminated varicella zoster virus infection with encephalitis in a UC patient receiving infliximab. Gastroenterol Hepatol (NY). 2013;9:54\u20136.","journal-title":"Gastroenterol Hepatol (NY)"},{"key":"3768_CR13","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1684\/ejd.2014.2331","volume":"24","author":"T Miyagi","year":"2014","unstructured":"Miyagi T, Yamaguchi S, Yamamoto Y, Ohira A, Yasumura R, Nakasone N, et al. Varicella zoster virus encephalopathy in a patient with psoriatic arthritis treated with anti-TNF\u03b1 agents. Eur J Dermatol. 2014;24:398\u20139.","journal-title":"Eur J Dermatol"},{"key":"3768_CR14","first-page":"271","volume":"33","author":"G Buccoliero","year":"2010","unstructured":"Buccoliero G, Lonero G, Romanelli C, Loperfido P, Resta F. Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-alpha agent in a psoriatic arthritis patient. New Microbiol. 2010;33:271\u20134.","journal-title":"New Microbiol"},{"key":"3768_CR15","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1468-3083.2006.01984.x","volume":"21","author":"DH Lee","year":"2007","unstructured":"Lee DH, Kim HS, Song YW, Cho KH. Development of varicella during adalimumab therapy. J Eur Acad Dermatol Venereol. 2007;21:687\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3768_CR16","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1159\/000149311","volume":"217","author":"S Becart","year":"2008","unstructured":"Becart S, Segaert S. Recurrent varicella in an adult psoriasis patient treated with etanercept. Dermatology. 2008;217:260\u20131.","journal-title":"Dermatology"},{"key":"3768_CR17","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","volume":"368","author":"U Heininger","year":"2006","unstructured":"Heininger U, Seward JF. Varicella. Lancet. 2006;368:1365\u201376.","journal-title":"Lancet"},{"key":"3768_CR18","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1542\/peds.109.6.1068","volume":"109","author":"S Hall","year":"2002","unstructured":"Hall S, Maupin T, Seward J, Jumaan AO, Peterson C, Goldman G, et al. Second varicella infections: are they more common than previously thought? Pediatrics. 2002;109:1068\u201373.","journal-title":"Pediatrics"},{"key":"3768_CR19","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1093\/cid\/cir033","volume":"52","author":"JA Johnson","year":"2011","unstructured":"Johnson JA, Bloch KC, Dang BN. Varicella reinfection in a seropositive physician following occupational exposure to localized zoster. Clin Infect Dis. 2011;52:907\u20139.","journal-title":"Clin Infect Dis"},{"key":"3768_CR20","doi-asserted-by":"publisher","first-page":"221","DOI":"10.7326\/0003-4819-108-2-221","volume":"108","author":"SE Straus","year":"1988","unstructured":"Straus SE, Ostrove JM, Inchausp\u00e9 G, Felser JM, Freifeld A, Croen KD, et al. NIH conference. Varicella-zoster virus infections. Biology, natural history, treatment, and prevention. Ann Intern Med. 1988;108:221.","journal-title":"Ann Intern Med"},{"key":"3768_CR21","first-page":"265","volume":"89","author":"WHO","year":"2014","unstructured":"WHO. Varicella and herpes zoster vaccines. WHO Position Paper. 2014;89:265\u201388.","journal-title":"WHO Position Paper"},{"key":"3768_CR22","unstructured":"European Medicines Agency. Humira. Summary of product characteristics. 2015. Available from: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000481\/WC500050870.pdf . Accessed 20 Oct 2018."},{"key":"3768_CR23","unstructured":"US Food and Drug Administration: Humira. Highlights of prescribing information 2008. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125057s114lbl.pdf . Accessed 20 Oct 2018."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3768-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12879-019-3768-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-019-3768-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T16:27:48Z","timestamp":1720974468000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-019-3768-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,7]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["3768"],"URL":"https:\/\/doi.org\/10.1186\/s12879-019-3768-y","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2019,2,7]]},"assertion":[{"value":"12 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal, upon request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"127"}}